According to Prof. Robert Sauerwein of Radboud University Nijmegen Medical Centre and principal investigator and coordinator of this project, Sanaria's methods for vaccine production are based on exceptional technological advances. The clinical tests will take place in Nijmegen, the Netherlands. Sauerwein: "The research being carried out by the groups at Radboud University Nijmegen Medical Centre and Leiden University Medical Center (research led by Dr. Chris Janse) will add a powerful new tool to the approach of rendering the parasite harmless, or attenuated. As opposed to weakening the parasites by radiation we wish to weaken them by genetically modifying them, leading to a similar result: an effective protection against malaria for humans."
Daan Crommelin, scientific director of TI Pharma states that this project will make a difference. "An effective malaria vaccine is important for millions of people in developing countries, especially for infants and children. Therefore this is a very important project based on the WHO Priority Medicines Program, in which malaria is specifically prioritized. With this unique cooperation between a front-running company such as Sanaria Inc. and two excellent Dutch medical centers, both leaders in the field, we expect major steps in the fight against malaria."
Sanaria Inc. was founded in 2003. The company's primary mission is to
develop and commercialize a malaria sporozoite vaccine against Plasmodium
falciparum, the parasite responsible for more than 95 percent of malaria
associated severe illness and death world-wide, and the malaria parasite
for which there is the most significant drug resistance. Sanaria has
overcome the initial technological and regulatory barriers and launched a
|SOURCE TI Pharma|
Copyright©2008 PR Newswire.
All rights reserved